{"product_id":"evidence-based-dermatology-isbn-9781118357675","title":"Evidence-Based Dermatology","description":"\u003cp\u003e\u003cb\u003eBe sure your skin-care treatments have strong evidential support\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003ci\u003eEvidence-based Dermatology, Third Edition\u003c\/i\u003e takes a unique approach to clinical dermatology by emphasising use of only the highest quality available evidence when treating people with skin diseases.\u003c\/p\u003e \u003cp\u003eBeginning with a toolbox introduction to the practice of evidence-based dermatology, it then covers the application of evidence for dermatological treatments across a wide range of ailments, including:\u003c\/p\u003e \u003cul\u003e \u003cli\u003eCommon inflammatory skin diseases\u003c\/li\u003e \u003cli\u003eSkin cancer, moles and actinic keratoses\u003c\/li\u003e \u003cli\u003eInfective skin disease, exanthems and infestations\u003c\/li\u003e \u003cli\u003eDisorders of pigmentation\u003c\/li\u003e \u003c\/ul\u003e \u003cp\u003eIn addition, many of the rarer skin disorders are also included so as to provide comprehensive coverage of the topic.\u003c\/p\u003e \u003cp\u003eWorld-leading experts in dermatology follow a clinical approach for each disease, and as well as providing their expert guidance on the description and diagnosis of dermatologic disorders, they also discuss common dilemmas that clinicians face when considering the best approach to patient management. 'Key Points' accompany each chapter to provide a quick review of the most important points.\u003c\/p\u003e \u003cp\u003eClinically oriented and practically focused, \u003ci\u003eEvidence-based Dermatology\u003c\/i\u003e ensures that your treatments are entirely patient-focused and fully supported by the very latest medical evidence.\u003c\/p\u003e  \u003cp\u003eContributors, viii\u003c\/p\u003e \u003cp\u003eForeword, xii\u003c\/p\u003e \u003cp\u003ePreface, xiv\u003c\/p\u003e \u003cp\u003eAbout the companion website, xv\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePART I: The concept of evidence-based dermatology\u003c\/b\u003e\u003cbr\u003e \u003ci\u003e\u003cb\u003eAndrew Herxheimer, editor\u003c\/b\u003e\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e1 The field and its boundaries, 3\u003cbr\u003e \u003ci\u003eLuigi Naldi\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e2 The rationale for evidence-based dermatology, 7\u003cbr\u003e \u003ci\u003eHywel C. Williams and Michael Bigby\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e3 The role of patient and public involvement in evidence-based dermatology, 12\u003cbr\u003e \u003ci\u003eCarron Layfield, Amanda Roberts, Jason Simons, Colette O'Sullivan, Anjna Rani, and Kim Thomas\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e4 The Cochrane Skin Group, 17\u003cbr\u003e \u003ci\u003eFinola Delamere, Liz Doney, Laura Prescott, and Shirley Manknell\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePART II: The critical appraisal toolbox\u003c\/b\u003e\u003cbr\u003e \u003ci\u003e\u003cb\u003eMichael Bigby, editor\u003c\/b\u003e\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e5 Formulating well-built clinical questions, 25\u003cbr\u003e \u003ci\u003eMichael Bigby and Berthold Rzany\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e6 Finding the best evidence, 27\u003cbr\u003e \u003ci\u003eMichael Bigby and Rosamaria Corona\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e7 The hierarchy of evidence, 30\u003cbr\u003e \u003ci\u003eMichael Bigby\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e8 Appraising systematic reviews and meta-analyses, 33\u003cbr\u003e \u003ci\u003eMichael Bigby and Hywel C. Williams\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e9 How to critically appraise a randomized controlled trial, 39\u003cbr\u003e \u003ci\u003eHywel C. Williams\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e10 Assessing and explaining the evidence on harms of medical interventions, 46\u003cbr\u003e \u003ci\u003eLuigi Naldi\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e11 How to evaluate diagnostic tests, 50\u003cbr\u003e \u003ci\u003eJoerg Albrecht and Michael Bigby\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e12 What makes a good case series?, 54\u003cbr\u003e \u003ci\u003eJoerg Albrecht and Michael Bigby\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e13 What makes a good prevalence survey?, 58\u003cbr\u003e \u003ci\u003eHywel C. Williams\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e14 Critical appraisal of pharmacoeconomic studies, 62\u003cbr\u003e \u003ci\u003eRajini K. Murthy, Laura K. DeLong, and Suephy C. Chen\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e15 Comparative effectiveness research: what it is and how to assess its quality, 66\u003cbr\u003e \u003ci\u003eJunko Takeshita and Joel M. Gelfand\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e16 Outcome measures, 71\u003cbr\u003e \u003ci\u003eAlain Dupuy, Emilie Sbidian, and Sylvie Bastuji-Garin\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e17 Where does qualitative research fit into evidence-based dermatology?, 75\u003cbr\u003e \u003ci\u003eRay Jobling and Luigi Naldi\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e18 Applying the evidence back to the patient, 79\u003cbr\u003e \u003ci\u003eHywel C. Williams\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePART III: The evidence\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eSECTION 1: Common inflammatory skin diseases\u003c\/b\u003e\u003cbr\u003e \u003ci\u003e\u003cb\u003eLuigi Naldi, editor\u003c\/b\u003e\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e19 Acne vulgaris, 87\u003cbr\u003e \u003ci\u003eMichael Romano and Robert P. Dellavalle\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e20 Papulopustular rosacea, 106\u003cbr\u003e \u003ci\u003eAlfredo Rebora and Francesco Drago\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e21 Perioral dermatitis, 112\u003cbr\u003e \u003ci\u003eVincenzo Bettoli, Stefania Zauli, and Annarosa Virgili\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e22 Hand eczema, 117\u003cbr\u003e Wietske A. Christoffers, Marie-Louise Anna Schuttelaar, and Pieter-Jan Coenraads\u003c\/p\u003e \u003cp\u003e23 The primary prevention of atopic dermatitis, 127\u003cbr\u003e \u003ci\u003eJoanne R. Chalmers, Sam F. Bremmer, and Eric L. Simpson\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e24 Atopic eczema, 136\u003cbr\u003e \u003ci\u003eKim Thomas, Carolyn Charman, Helen Nankervis, Jane Ravenscroft, and Hywel C. Williams\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e25 Seborrheic dermatitis, 169\u003cbr\u003e \u003ci\u003eMauro Picardo and Norma Cameli\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e26 Treatment of psoriasis, 175\u003cbr\u003e \u003ci\u003eAlexander Nast, Phyllis Spuls, and Tamar Nijsten\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e27 Lichen planus, 200\u003cbr\u003e \u003ci\u003eLaurence Le Cleach and Olivier Chosidow\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e28 Acute urticaria, 206\u003cbr\u003e \u003ci\u003eTorsten Schafer\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e29 Chronic urticaria, 210\u003cbr\u003e \u003ci\u003eKarsten Weller and Marcus Maurer\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eSECTION 2: Skin cancer, moles, and actinic keratoses\u003c\/b\u003e\u003cbr\u003e \u003ci\u003e\u003cb\u003eRobert Dellavalle, editor\u003c\/b\u003e\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e30 Primary prevention of skin cancer, 223\u003cbr\u003e \u003ci\u003eMonika Janda and Adele C. Green\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e31 Treatment of cutaneous melanoma, 231\u003cbr\u003e \u003ci\u003eMary Ann N. Johnson and April W. Armstrong\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e32 Treatment of squamous cell carcinoma, 241\u003cbr\u003e \u003ci\u003eLouise Lansbury, William Perkins, and Fiona Bath-Hextall\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e33 Basal cell carcinoma, 250\u003cbr\u003e \u003ci\u003eFiona Bath-Hextall and William Perkins\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e34 Primary cutaneous T-cell lymphoma, 264\u003cbr\u003e \u003ci\u003eFiona Child and Sean Whittaker\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e35 Actinic keratosis and Bowen's disease, 283\u003cbr\u003e \u003ci\u003eSasha N. Jenkins, Maren Speck, and Suephy C. Chen\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e36 Kaposi sarcoma, 303\u003cbr\u003e \u003ci\u003eWhitney A. High\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e37 Melanocytic nevi, 313\u003cbr\u003e \u003ci\u003eVarun Shahi and Jerry D. Brewer\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eSECTION 3: Infective skin diseases, exanthems, and infestations\u003c\/b\u003e\u003cbr\u003e \u003ci\u003e\u003cb\u003eMasutaka Furue and Yuping Ran, editors\u003c\/b\u003e\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e38 Local treatments for cutaneous warts, 320\u003cbr\u003e \u003ci\u003eJuping Chen and Yan Wu\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e39 Molluscum contagiosum, 329\u003cbr\u003e \u003ci\u003eMinh L. Lam\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e40 Impetigo, 337\u003cbr\u003e \u003ci\u003eSander Koning, Renske van der Sande, Lisette W.A. van Suijlekom-Smit, and Johannes C. van der Wouden\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e41 Athlete's foot, 341\u003cbr\u003e \u003ci\u003eInajara Rotta, Michel F. Otuki, and Cassyano J. Correr\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e42 Pityriasis versicolor, 345\u003cbr\u003e \u003ci\u003eNancy Habib and Michael Bigby\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e43 Onychomycosis, 349\u003cbr\u003e \u003ci\u003eAditya K. Gupta, Elizabeth A. Cooper, Maryse Paquet, and Fiona Simpson\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e44 Tinea capitis, 364\u003cbr\u003e \u003ci\u003eUrba Gonzalez\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e45 Deep fungal infections, 371\u003cbr\u003e \u003ci\u003eRoderick J. Hay\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e46 Streptococcal cellulitis\/erysipelas of the lower leg, 378\u003cbr\u003e \u003ci\u003eVinod E. Nambudiri and Michael Bigby\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e47 Exanthematic reactions, 388\u003cbr\u003e \u003ci\u003eSandra R. Knowles and Neil H. Shear\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e48 Herpes simplex, 396\u003cbr\u003e \u003ci\u003eVera Mahler\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e49 Leprosy, 407\u003cbr\u003e \u003ci\u003eSaumya Panda\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e50 Cutaneous leishmaniasis, 421\u003cbr\u003e \u003ci\u003eUrba Gonzalez, Armando Ruiz-Baques, and Jorge Alvar\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e51 Scabies, 432\u003cbr\u003e \u003ci\u003eIan F. Burgess\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e52 Head lice, 441\u003cbr\u003e \u003ci\u003eIan F. Burgess and Ciara S. Casey\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e53 Insect bites and stings, 451\u003cbr\u003e \u003ci\u003eBelen Lardizabal Dofitas\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eSECTION 4: Disorders of pigmentation\u003c\/b\u003e\u003cbr\u003e \u003ci\u003e\u003cb\u003eHywel C. Williams, editor\u003c\/b\u003e\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e54 Vitiligo, 464\u003cbr\u003e \u003ci\u003eJuan Jorge Manriquez and Sergio M. Niklitschek\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e55 Melasma, 470\u003cbr\u003e \u003ci\u003eAsad Salim, Ratna Rajaratnam, and Eva Soos Domanne\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eSECTION 5: Common ailments with significant cosmetic impact\u003c\/b\u003e\u003cbr\u003e \u003ci\u003e\u003cb\u003eBerthold Rzany, editor\u003c\/b\u003e\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e56 Male and female androgenetic alopecia, 486\u003cbr\u003e \u003ci\u003eHans Wolff and Kathrin Giehl\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e57 Alopecia areata, 490\u003cbr\u003e \u003ci\u003eRod Sinclair\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e58 Evidence-based treatment of hirsutism, 498\u003cbr\u003e \u003ci\u003eUlrike Blume-Peytavi and Natalie Garcia-Bartels\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e59 Focal hyperhidrosis, 504\u003cbr\u003e \u003ci\u003eKave Shams and Berthold Rzany\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e60 Dermal fillers, 512\u003cbr\u003e \u003ci\u003eStephanie Ogden and Tamara Griffiths\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e61 Reducing mimic wrinkles and folds with botulinum toxin A, 516\u003cbr\u003e \u003ci\u003eBerthold Rzany\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eSECTION 6: Other important skin disorders\u003c\/b\u003e\u003cbr\u003e \u003ci\u003e\u003cb\u003eMichael Bigby, editor\u003c\/b\u003e\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e62 Cutaneous lupus erythematosus, 523\u003cbr\u003e \u003ci\u003eSusan Jessop and David Whitelaw\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e63 Dermatomyositis, 531\u003cbr\u003e \u003ci\u003eRuth Ann Vleugels, David F. Fiorentino, and Jeffrey P. Callen\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e64 Acquired subepidermal bullous diseases, 545\u003cbr\u003e \u003ci\u003eGudula Kirtschig, Vanessa Venning, Nonhlanhla P. Khumalo, and Fenella Wojnarowska\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e65 Pemphigus, 552\u003cbr\u003e \u003ci\u003eLinda K. Martin, Brian R. Sperber, Dedee F. Murrell, and Victoria P. Werth\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e66 Cutaneous sarcoidosis, 561\u003cbr\u003e \u003ci\u003eMisha Rosenbach and Joseph C. English III\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e67 Erythema multiforme, 575\u003cbr\u003e \u003ci\u003ePierre-Dominique Ghislain and Jean-Claude Roujeau\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e68 Stevens–Johnson syndrome and toxic epidermal necrolysis, 578\u003cbr\u003e \u003ci\u003eJean-Claude Roujeau, Pierre-Dominique Ghislain, and Laurence Valleyrie-Allanore\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e69 Polymorphic light eruption, 586\u003cbr\u003e \u003ci\u003eRobert S. Dawe\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e70 Infantile hemangiomas, 590\u003cbr\u003e \u003ci\u003eHossain Shahidullah\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e71 Pruritus, 595\u003cbr\u003e \u003ci\u003eElke Weisshaar and Gil Yosipovitch\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e72 Vulval lichen sclerosus, erosive lichen planus, and vulvodynia, 615\u003cbr\u003e \u003ci\u003eRosalind C. Simpson, Ruth Murphy, and David Nunns\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e73 Venous ulcers, 624\u003cbr\u003e \u003ci\u003eJonathan Kantor, David J. Margolis, and Douglas J. Pugliese\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e74 Other skin diseases for which trials exist, 632\u003cbr\u003e \u003ci\u003eSinead Langan and Hywel C. Williams\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePART IV: The future of evidence-based dermatology\u003c\/b\u003e\u003cbr\u003e \u003ci\u003e\u003cb\u003eLuigi Naldi, editor\u003c\/b\u003e\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e75 Where do we go from here?, 637\u003cbr\u003e \u003ci\u003eHywel C. Williams\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eSubject Index, 644\u003c\/p\u003e \u003cp\u003e\u003cb\u003eHywel Williams\u003c\/b\u003e, MBBS Department of Dermatology, Queen's Medical Centre, University of Nottingham, Nottingham, UK.\u003c\/p\u003e \u003cp\u003e\u003cb\u003eMichael Bigby\u003c\/b\u003e, MD, Department of Dermatology, Harvard Medical School, USA.\u003c\/p\u003e \u003cp\u003e\u003cb\u003eAndrew Herxheimer\u003c\/b\u003e, MBBS, UK Cochrane Centre.\u003c\/p\u003e \u003cp\u003e\u003cb\u003eLuigi Naldi\u003c\/b\u003e, M, Department of Dermatology, Ospedali Riuniti, Bergamo, Italy.\u003c\/p\u003e \u003cp\u003e\u003cb\u003eBerthold Rzany\u003c\/b\u003e, MD, Division of EBM, Klinik fur Dermatologie, Charite-Universitatsmedizin, Berlin, Germany.\u003c\/p\u003e \u003cp\u003e\u003cb\u003eRobert Dellavalle\u003c\/b\u003e, MD, Chief, Dermatology Service, Denver VA Medical Center, USA.\u003c\/p\u003e \u003cp\u003e\u003cb\u003eYuping Ran\u003c\/b\u003e, MD, Department of Dermatology, Sichuan University, China.\u003c\/p\u003e \u003cp\u003e\u003cb\u003eMasutaka Furue\u003c\/b\u003e, MD, Department of Dermatology, Kyushu University, Japan.\u003c\/p\u003e \u003cp\u003eEVIDENCE-BASED DERMATOLOGY THIRD EDITION\u003c\/p\u003e \u003cp\u003eEdited by Hywel C. Williams, DSc, FRCP, Centre of Evidence Based Dermatology, University of Nottingham, Nottingham, UK\u003c\/p\u003e \u003cp\u003e\u003cb\u003eBe sure your skin-care treatments have strong evidential support\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003ci\u003eEvidence-based Dermatology, Third Edition\u003c\/i\u003e takes a unique approach to clinical dermatology by emphasising use of only the highest quality available evidence when treating people with skin diseases.\u003c\/p\u003e \u003cp\u003eBeginning with a toolbox introduction to the practice of evidence-based dermatology, it then covers the application of evidence for dermatological treatments across a wide range of ailments, including:\u003c\/p\u003e \u003cul\u003e \u003cli\u003eCommon inflammatory skin diseases\u003c\/li\u003e \u003cli\u003eSkin cancer, moles and actinic keratoses\u003c\/li\u003e \u003cli\u003eInfective skin disease, exanthems and infestations\u003c\/li\u003e \u003cli\u003eDisorders of pigmentation\u003c\/li\u003e \u003c\/ul\u003e \u003cp\u003eIn addition, many of the rarer skin disorders are also included so as to provide comprehensive coverage of the topic.\u003c\/p\u003e \u003cp\u003eWorld-leading experts in dermatology follow a clinical approach for each disease, and as well as providing their expert guidance on the description and diagnosis of dermatologic disorders, they also discuss common dilemmas that clinicians face when considering the best approach to patient management. 'Key Points' accompany each chapter to provide a quick review of the most important points.\u003c\/p\u003e \u003cp\u003eClinically oriented and practically focused, \u003ci\u003eEvidence-based Dermatology\u003c\/i\u003e ensures that your treatments are entirely patient-focused and fully supported by the very latest medical evidence.\u003c\/p\u003e","brand":"Wiley-Blackwell","offers":[{"title":"Default Title","offer_id":47989175222501,"sku":"NP9781118357675","price":465.95,"currency_code":"USD","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1842\/7735\/files\/9781118357675.jpg?v=1761783093","url":"https:\/\/k12savings.com\/products\/evidence-based-dermatology-isbn-9781118357675","provider":"K12savings","version":"1.0","type":"link"}